Xenon Pharmaceuticals Announces Exceptionally Positive Phase 3 Results for Azetukalner in Focal Onset Seizures

Key Highlights

• Phase 3 X-TOLE2 Study: Azetukalner achieved its primary endpoint in both dose groups, demonstrating robust efficacy in reducing focal onset seizures (FOS).
• Magnitude of Efficacy: The 25 mg dose group showed a remarkable -53.2% median percent change (MPC) in monthly FOS frequency versus baseline, compared to -10.4% for placebo (p=0.000000000006). The placebo-adjusted MPC was -42.7% – reportedly the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study.
• Secondary Endpoint: 54.8% of patients in the 25 mg group and 37.6% in the 15 mg group achieved ≥50% reduction in seizure frequency (RR50), compared to 20.8% in placebo (p=0.00000008 and p=0.003, respectively).
• Safety Profile: Azetukalner was generally well-tolerated. The most common side effects were dizziness, headache, somnolence, and fatigue. Serious adverse events were rare and similar across all groups.
• Regulatory Milestone: Xenon plans to submit a New Drug Application (NDA) for azetukalner to the U.S. FDA in Q3 2026. If approved, it would be the only K V 7 potassium channel opener available for epilepsy.
• Commercial Potential: Xenon is preparing for its first commercial launch, with more than 800 patient-years of exposure data supporting azetukalner’s efficacy and safety.
• Upcoming Presentation: X-TOLE2 data will be featured in a Late Breaking Science oral presentation at the American Academy of Neurology (AAN) Annual Meeting in April.

Detailed Study Results

The X-TOLE2 clinical trial (NCT05614063) was a randomized, double-blind, placebo-controlled, multicenter Phase 3 study evaluating azetukalner as an adjunctive, once-daily oral therapy in adults with highly treatment-resistant focal onset seizures. The trial included 380 randomized participants, with 374 in the safety and modified intent-to-treat population. The cohort had a median of five prior antiseizure medications (ASMs), a baseline seizure frequency of 12.75/month, and 51.3% were on three concomitant ASMs. Of 332 who completed the double-blind period, 322 entered the open-label extension.

Primary Endpoint

• Azetukalner 25 mg: -53.2% MPC in monthly FOS frequency (p=0.000000000006)
• Azetukalner 15 mg: -34.5% MPC (p=0.00007)
• Placebo: -10.4% MPC
• Placebo-adjusted MPC (25 mg): -42.7%, significantly outperforming the prior Phase 2b X-TOLE study (-34.6%)

Key Secondary Endpoint (RR50)

• Azetukalner 25 mg: 54.8% achieved ≥50% seizure reduction (p=0.00000008)
• Azetukalner 15 mg: 37.6% achieved ≥50% seizure reduction (p=0.003)
• Placebo: 20.8%

Safety and Tolerability

The safety profile of azetukalner was consistent with prior studies. The most frequent treatment-emergent adverse events (TEAEs) for azetukalner were:

• Dizziness (20.5%)
• Headache (8.8%)
• Somnolence (8.8%)
• Fatigue (7.6%)

For placebo: dizziness (3.2%), headache (6.4%), somnolence (7.2%), fatigue (6.4%). TEAEs leading to discontinuation occurred in 14.5% (25 mg), 4.8% (15 mg), and 3.2% (placebo). Serious TEAEs were low: 5.6% (25 mg), 3.2% (15 mg), 2.4% (placebo).

Market and Commercial Implications

Epilepsy affects around three million adults in the U.S., and up to half of people with focal epilepsy have uncontrolled seizures despite polytherapy. Azetukalner’s differentiated mechanism (K V 7 potassium channel opener) and favorable clinical profile – including no need for titration, once-daily dosing, and minimal drug interactions – position it as a potential game-changer in the epilepsy market.

Xenon is advancing commercial readiness and expects to submit its NDA in Q3 2026. Given the strong efficacy, safety, and ease-of-use, azetukalner could become a preferred treatment for patients with uncontrolled seizures, representing a significant opportunity for Xenon and a potentially transformative event for shareholders.

Additional Pipeline and Corporate Information

Xenon is also developing potassium and sodium channel modulators for pain, major depressive disorder, and bipolar depression, further broadening its pipeline and future revenue streams. The company has offices in Vancouver and Boston, and is preparing for its first commercial product launch.

Upcoming Events

• Xenon will host a conference call and webcast to discuss X-TOLE2 results. Access details: (800) 715-9871 / (646) 307-1963, conference ID 7885306.
• Late Breaking Science oral presentation at the AAN Annual Meeting, April 19th, Chicago.

Shareholder Considerations

• The X-TOLE2 results are exceptionally strong, with efficacy exceeding previous benchmarks and a safety profile consistent with prior studies.
• The planned NDA submission and potential commercial launch in 2026 could create significant value inflection points.
• Azetukalner represents a first-in-class, differentiated therapy in a large, underserved market.
• Any regulatory delays, safety concerns, or competitive developments could impact share value. Investors should monitor clinical and regulatory progress closely.

Disclaimer: The above article is based on information provided by Xenon Pharmaceuticals and is intended for informational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell securities. All forward-looking statements are subject to risks and uncertainties, including those detailed in Xenon’s regulatory filings. Investors should conduct their own due diligence and consult professional advisers before making any investment decisions.

View Xenon Pharmaceuticals Inc. Historical chart here